FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310588840> ?p ?o ?g. }

• W4310588840 endingPage "38" @default.
• W4310588840 startingPage "27" @default.
• W4310588840 abstract "The persistence of elevated rates of ischemic recurrences despite the use of antiplatelet therapy among patients with atherosclerotic disease together with the understanding of the pivotal role of coagulation in the thrombo-inflammatory processes involved in the pathogenesis of atherosclerosis and its complications has fostered the development of treatments targeting both platelets and coagulation, a strategy known as dual-pathway inhibition (DPI).In this review we discuss the recent advancements in the understanding of the interplay between coagulation, platelets and inflammation involved in the pathophysiology of atherosclerosis and atherothrombosis, as the rationale for the implementation of a DPI strategy. We also discuss the available pharmacodynamic (PD) evidence and clinical implications with the use of DPI in patients with atherosclerotic disease.The implementation of a DPI by adding the so-called 'vascular dose of rivaroxaban' (i.e. 2.5 mg bis in die), on top of antiplatelet therapy has consistently been associated with reduced levels of thrombin generation in PD studies and with reduced ischemic event rates at the cost of increased bleeding compared to antiplatelet therapy alone. Further research is warranted to best define patients in whom a DPI regimen has the best safety and efficacy profile." @default.
• W4310588840 created "2022-12-12" @default.
• W4310588840 creator A5002630544 @default.
• W4310588840 creator A5014287819 @default.
• W4310588840 creator A5016139987 @default.
• W4310588840 creator A5024294469 @default.
• W4310588840 creator A5028730426 @default.
• W4310588840 creator A5029130187 @default.
• W4310588840 creator A5033442682 @default.
• W4310588840 creator A5040418600 @default.
• W4310588840 creator A5067302152 @default.
• W4310588840 date "2022-12-12" @default.
• W4310588840 modified "2023-10-18" @default.
• W4310588840 title "Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications" @default.
• W4310588840 cites W1553345686 @default.
• W4310588840 cites W1564690174 @default.
• W4310588840 cites W1965317284 @default.
• W4310588840 cites W1984763915 @default.
• W4310588840 cites W2018383335 @default.
• W4310588840 cites W2083500854 @default.
• W4310588840 cites W2086997894 @default.
• W4310588840 cites W2098837786 @default.
• W4310588840 cites W2102785524 @default.
• W4310588840 cites W2108064339 @default.
• W4310588840 cites W2117677020 @default.
• W4310588840 cites W2121366426 @default.
• W4310588840 cites W2123973590 @default.
• W4310588840 cites W2127090290 @default.
• W4310588840 cites W2140501627 @default.
• W4310588840 cites W2159370562 @default.
• W4310588840 cites W2168719124 @default.
• W4310588840 cites W2169387542 @default.
• W4310588840 cites W2342473733 @default.
• W4310588840 cites W2556414715 @default.
• W4310588840 cites W2596358769 @default.
• W4310588840 cites W2749380187 @default.
• W4310588840 cites W2754054868 @default.
• W4310588840 cites W2765277184 @default.
• W4310588840 cites W2767660506 @default.
• W4310588840 cites W2793659838 @default.
• W4310588840 cites W2795076463 @default.
• W4310588840 cites W2888292644 @default.
• W4310588840 cites W2907012814 @default.
• W4310588840 cites W2968796809 @default.
• W4310588840 cites W2973841278 @default.
• W4310588840 cites W2995526000 @default.
• W4310588840 cites W2999002463 @default.
• W4310588840 cites W3011371150 @default.
• W4310588840 cites W3013428853 @default.
• W4310588840 cites W3037187678 @default.
• W4310588840 cites W3080801838 @default.
• W4310588840 cites W3096554873 @default.
• W4310588840 cites W3107201513 @default.
• W4310588840 cites W3126369559 @default.
• W4310588840 cites W3159729619 @default.
• W4310588840 cites W3162195278 @default.
• W4310588840 cites W3172069150 @default.
• W4310588840 cites W3189369858 @default.
• W4310588840 cites W4206668148 @default.
• W4310588840 cites W4210612718 @default.
• W4310588840 cites W4211134725 @default.
• W4310588840 cites W4221013898 @default.
• W4310588840 cites W4223439574 @default.
• W4310588840 cites W4225526112 @default.
• W4310588840 cites W4229000162 @default.
• W4310588840 cites W4282599402 @default.
• W4310588840 cites W4283727253 @default.
• W4310588840 cites W4293410865 @default.
• W4310588840 cites W4296902187 @default.
• W4310588840 doi "https://doi.org/10.1080/17512433.2023.2154651" @default.
• W4310588840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36455906" @default.
• W4310588840 hasPublicationYear "2022" @default.
• W4310588840 type Work @default.
• W4310588840 citedByCount "2" @default.
• W4310588840 countsByYear W43105888402023 @default.
• W4310588840 crossrefType "journal-article" @default.
• W4310588840 hasAuthorship W4310588840A5002630544 @default.
• W4310588840 hasAuthorship W4310588840A5014287819 @default.
• W4310588840 hasAuthorship W4310588840A5016139987 @default.
• W4310588840 hasAuthorship W4310588840A5024294469 @default.
• W4310588840 hasAuthorship W4310588840A5028730426 @default.
• W4310588840 hasAuthorship W4310588840A5029130187 @default.
• W4310588840 hasAuthorship W4310588840A5033442682 @default.
• W4310588840 hasAuthorship W4310588840A5040418600 @default.
• W4310588840 hasAuthorship W4310588840A5067302152 @default.
• W4310588840 hasConcept C10162356 @default.
• W4310588840 hasConcept C111113717 @default.
• W4310588840 hasConcept C112705442 @default.
• W4310588840 hasConcept C126322002 @default.
• W4310588840 hasConcept C203014093 @default.
• W4310588840 hasConcept C2776301958 @default.
• W4310588840 hasConcept C2776914184 @default.
• W4310588840 hasConcept C2778382381 @default.
• W4310588840 hasConcept C2778661090 @default.
• W4310588840 hasConcept C2779134260 @default.
• W4310588840 hasConcept C2779161974 @default.
• W4310588840 hasConcept C2780942790 @default.
• W4310588840 hasConcept C3018697912 @default.

• next